William Blair Initiates Coverage on LENZ Therapeutics (NASDAQ:LENZ)

William Blair started coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research report sent to investors on Monday morning, Marketbeat.com reports. The brokerage issued an outperform rating on the stock.

A number of other research analysts also recently weighed in on the stock. Piper Sandler started coverage on shares of LENZ Therapeutics in a research report on Wednesday, March 27th. They set an overweight rating and a $28.00 price objective on the stock. Citigroup initiated coverage on shares of LENZ Therapeutics in a research note on Wednesday, April 10th. They set a buy rating and a $34.00 target price for the company.

LENZ Therapeutics Price Performance

Shares of LENZ Therapeutics stock opened at $20.44 on Monday. The stock has a market capitalization of $170.06 million, a price-to-earnings ratio of -1.31 and a beta of 0.20. LENZ Therapeutics has a 52-week low of $14.07 and a 52-week high of $29.82.

Insider Buying and Selling at LENZ Therapeutics

In related news, Director Ra Capital Management, L.P. bought 998,009 shares of the firm’s stock in a transaction on Thursday, March 21st. The stock was acquired at an average cost of $15.03 per share, for a total transaction of $15,000,075.27. Following the purchase, the director now owns 3,319,339 shares in the company, valued at $49,889,665.17. The acquisition was disclosed in a filing with the SEC, which is available through this link. Company insiders own 38.40% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.